ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-16,965.00%
ROE
-19.10%
ROA
-14.50%
Debt/equity
0.05x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $2.32M | $-1.04B | 73.92% | -32,206.97% | -44,835.15% |
| 2020 | $67.69M | $1.20B | 98.33% | -786.58% | 1,773.57% |
| 2021 | $23.80M | $-809.23M | 91.36% | -4,500.52% | -3,400.86% |
| 2022 | $55.29M | $-845.26M | 83.78% | -2,444.82% | -1,528.89% |
| 2023 | $61.28M | $-1.01B | 78.58% | -1,917.95% | -1,646.59% |
| 2024 | $32.71M | $4.35B | 95.11% | 13,746.93% | 13,294.18% |
| 2025 | $29.05M | $-171.98M | 96.86% | -3,453.32% | -591.96% |